EROX — Human Pheromone Sciences Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | 9.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2006 | 2007 | 2008 | 2009 | 2010 | 2011E | 2012E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.23 | 1.29 | 0.99 | 0.89 | 0.81 | n/a | n/a | 14.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Human Pheromone Sciences, Inc. is a science based company. The Company produces all Natural Attraction products. The Company engages in the research, development, manufacturing and marketing of human pheromones and consumer products containing human pheromones as a component. The Company focuses on the development of human-pheromone based products under its Natural Attraction brand and licenses other companies to use the Company's patented technology in their proprietary brands and products. The Company distributes these products via www.naturalattraction.com. The Company has developed a line of fragrance products for men and women under the, Natural Attraction name. The Company’s research and development laboratories are in Salt Lake City, Utah.
Directors
- William Horgan CHM (63)
- Gregory Fredrick CFO (56)
- Bernard Grosser IND (82)
- Helen Leong IND (83)
- Carson Tang IND (51)
- Last Annual
- December 31st, 2010
- Last Interim
- September 30th, 2011
- Incorporated
- November 28th, 1989
- Public Since
- January 26th, 1993
- No. of Shareholders
- 530
- No. of Employees
- 2
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 4,151,954
- Address
- 1267 Willis St. #200, REDDING, 96001
- Web
- Phone
- +1 4089383030
- Auditors
- SingerLewak LLP
Similar to EROX
American Education Center
Pink Sheets on Nasdaq
Arem Pacific
Pink Sheets on Nasdaq
Axia International
Pink Sheets on Nasdaq
Ascendia Brands
Pink Sheets on Nasdaq
Aspen
Pink Sheets on Nasdaq
FAQ
As of Today at 18:10 UTC, shares in Human Pheromone Sciences are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Human Pheromone Sciences last closed at $0.00 and the price had moved by -96% over the past 365 days. In terms of relative price strength the Human Pheromone Sciences share price has underperformed the S&P500 Index by -96.38% over the past year.
There is no consensus recommendation for this security.
Human Pheromone Sciences does not currently pay a dividend.
Human Pheromone Sciences does not currently pay a dividend.
Human Pheromone Sciences does not currently pay a dividend.
To buy shares in Human Pheromone Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Human Pheromone Sciences had a market capitalisation of .
Here are the trading details for Human Pheromone Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EROX
Based on an overall assessment of its quality, value and momentum Human Pheromone Sciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Human Pheromone Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -98.93%.
As of the last closing price of $0.00, shares in Human Pheromone Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Human Pheromone Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Human Pheromone Sciences' management team is headed by:
- William Horgan - CHM
- Gregory Fredrick - CFO
- Bernard Grosser - IND
- Helen Leong - IND
- Carson Tang - IND